Can Fam Physician. 1983 Apr;29:703-8.
Nifedipine, a calcium channel blocking drug with vasodilating action in both systemic and coronary arterial beds, was administered to 79 patients with a variety of ischemic heart diseases. Forty-five variant angina patients given a mean daily dose of 78 mg experienced a reduction from 2.6 to 0.28 attacks per day (p<0.001), confirmed by in-hospital ergonovine testing (22 patients) and outpatient 24-hour Holter monitoring (28 patients). Twenty-one stable post-acute myocardial infarction patients given a single 20 mg oral dose showed a significant (p<0.001) decrease in mean arterial pressure and systemic vascular resistance, accompanied by a significant (p<0.01) increase in cardiac index and heart rate, most noticeable in the patients with the worst ventricular function. Symptoms were relieved in nine of 13 patients with class III and IV refractory angina pectoris when nifedipine 40-80 mg was added to nitrate and beta blocker therapy. Of angina patients, 40% experienced mild side effects, but only 3% were forced to stop therapy due to peripheral edema. No serious hemodynamic or electrocardiographic toxicity occurred. Precautions should be taken if hepatic enzyme abnormalities or reflex tachycardia develop which may worsen angina. Diltiazem and verapamil have different hemodynamic effect and can be used advantageously in some clinical circumstances.
硝苯地平是一种钙通道阻滞剂,具有全身和冠状动脉床的血管扩张作用,已被用于 79 例各种缺血性心脏病患者。45 例变异型心绞痛患者平均每天给予 78 毫克,每日发作次数从 2.6 次减少到 0.28 次(p<0.001),通过住院内麦角新碱试验(22 例)和门诊 24 小时动态心电图监测(28 例)得到证实。21 例急性心肌梗死后稳定患者单次口服 20 毫克,平均动脉压和全身血管阻力显著下降(p<0.001),同时心指数和心率显著升高(p<0.01),在心室功能最差的患者中最为明显。当硝苯地平 40-80 毫克加用硝酸盐和β受体阻滞剂治疗时,13 例 III 级和 IV 级难治性心绞痛患者中的 9 例症状得到缓解。在心绞痛患者中,40%出现轻度副作用,但只有 3%因外周水肿被迫停止治疗。未发生严重的血液动力学或心电图毒性。如果出现肝酶异常或反射性心动过速,可能会加重心绞痛,应谨慎使用。地尔硫卓和维拉帕米具有不同的血液动力学作用,在某些临床情况下可以有利地使用。